Triple-action drug retatrutide delivers major weight loss for people with diabetes, Phase III trial finds
A recent Phase III clinical trial, TRIUMPH-2, evaluated the efficacy and safety of retatrutide, a triple receptor agonist and experimental once-weekly injection being developed to treat obesity and type 2 diabetes. What sets it apart from drugs such as semaglutide (Wegovy), which targets one hormone, and tirzepatide (Zepbound), which targets two, is its ability to activate three hormone receptors…
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Technology-assisted approach can help prevent summer weight gain in adolescents
-
Why managing vibration is critical in IVF
-
Neck stiffness puts pitchers at risk of throwing-related injuries
-
AI tool reveals what attracts immune cells to tumors and what keeps them away
-
New research shows reduced toxicant exposure reduces biological activity
-
11 hidratantes para pele oleosa (e como escolher)
-
AI screening helps more people with diabetes access sight-saving eye care
-
Exposure to 'safer' plastic additive during pregnancy linked to smaller birth size